Analyst Conference Summaries

Biotechnology Investor Aids

Protalix BioTherapeutics
PLX

conference date: November 7, 2018 @ 5:30 AM Pacific Time

FDA Okays Phase 3 Study of PRX-102 for Fabry Disease [November 16, 2015]

Protalix Positive Preclinical Results for NASH [October 5, 2015]
Protalix Positive Interim Phase I/II Data for PRX-102 [Jan. 8, 2015]
Protalix: Undervalued Growth, Plus a Possible Biotech Breakthrough [Oct. 30, 2013 @ Seeking Alpha]

2018
 
May 9, 2018
August 9, 2018
Nov. 7, 2018
 
2017
May 10, 2017
August 9, 2017
Nov. 8, 2017
March 6, 2018
2016
05/09/2016
08/08/2016
11/09/2016
03/16/2017
2015
 05/07/2015
08/10/2015 
 11/09/2015
 03/08/2016

Protalix BioTherapeutics (PLX) is a biotechnology company making proprietary recombinant therapeutic proteins with its ProCellEx plant cell based protein expression system.

Protalix does not currently hold quarterly conference calls for analysts. It is based in Israel, but registered in Florida and files with the SEC.

Protalix BioTherapeutics web site
Protalix investor relations page


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 BIIB
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INCY
 INO
 ISRG
 MCHP
 MYL.
 PLX
 REGN
 SGEN
 XLNX
 XLRN

 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. This is financial journalism, not advice..

Copyright 2018 William P. Meyers